HUYA Bioscience inks strategic deal to access China innovation

18 January 2017
huya-big

USA-based China orientated company HUYA Bioscience International has entered into a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (CAS Innovation).

The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

HUYA is the first company to have recognized China's potential as an important source of new innovative preclinical and clinical stage compounds. The company accelerates development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets. In keeping with this strategic vision, HUYA has already established over one hundred collaborations with leading universities, research institutes, and science parks throughout China.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical